People's Justice is not a law firm and does not provide legal advice.
Attorney advertising. Prior results do not guarantee a similar outcome.
Do You Qualify?
Eligibility Checklist
- Used a testosterone replacement therapy product (AndroGel, Axiron, Androderm, Testim, Fortesta, Depo-Testosterone, or generic equivalent) for at least 30 days
- Diagnosed with heart attack (myocardial infarction), stroke (ischemic or hemorrhagic), deep vein thrombosis (DVT), pulmonary embolism (PE), or polycythemia while using TRT or within 6 months of use
- Injury occurred after at least one month of TRT use
- Did not use TRT solely for documented primary hypogonadism diagnosed prior to 2008 Low T marketing campaign
- Within applicable state statute of limitations (typically 2–3 years from injury discovery; tolled for MDL Short Form Complaint filers)
Injured? Get a free Testosterone Therapy case review.
Get Your Free Case Reviewor call 1-800-555-0100
Testosterone replacement therapy litigation centers on manufacturer failure to adequately warn physicians and patients about cardiovascular risks that were known or knowable from emerging clinical evidence. The FDA's 2014 Drug Safety Communication and 2015 class-wide label revision confirmed the link between TRT and venous thromboembolism. Claims allege that manufacturers — particularly AbbVie with AndroGel — conducted aggressive direct-to-consumer advertising targeting men with normal age-related testosterone decline while suppressing or downplaying cardiovascular risk data. The MDL 2545 bellwether process tested key liability and causation theories. AbbVie's mixed bellwether record (some plaintiff verdicts, some defense wins) ultimately led to a confidential global settlement of its MDL inventory. Remaining defendants including Eli Lilly, Actavis/Teva, and Endo successor entities face ongoing litigation. The Endo bankruptcy creates a distinct claims pathway — affected plaintiffs must file proofs of claim with the bankruptcy trust rather than through traditional MDL process.
Testosterone Therapy Lawsuit Settlement Tiers
Settlement ranges are based on publicly reported MDL 2545 bellwether outcomes and plaintiffs' bar estimates. Actual compensation varies by injury severity, causation evidence, medical records quality, and defendant. These figures are illustrative only and do not constitute a guarantee of recovery.
DVT/PE — Full Recovery
ModerateSettlement Range
Criteria
- Diagnosed with deep vein thrombosis (DVT) or pulmonary embolism (PE) during or within 6 months of TRT use
- Full recovery with no permanent disability
- Clear TRT use timeline in medical records
- No significant pre-existing clotting disorders
Heart Attack — Survived with Recovery
SeriousSettlement Range
Criteria
- Diagnosed with myocardial infarction (heart attack) while using TRT
- Survived with moderate cardiac damage or residual effects
- TRT prescription records and cardiac records clearly linked
- No complete prior cardiovascular occlusion history
Stroke or Heart Attack with Permanent Disability
SevereSettlement Range
Criteria
- Suffered stroke (ischemic or hemorrhagic) or major heart attack with permanent disability
- Ongoing medical treatment, reduced earning capacity, or long-term care needs
- Strong causation timeline connecting TRT use to cardiovascular event
- Medical expert willing to testify on TRT-injury link
Death or Catastrophic Cardiac Event
CatastrophicSettlement Range
Criteria
- Wrongful death resulting from heart attack, stroke, or pulmonary embolism while on TRT
- Surviving spouse or dependent brings claim
- Strong prescription and autopsy or medical records
- Deceased had no terminal pre-existing condition that would have independently caused death
Settlement amounts listed are estimates based on publicly available information from MDL 2545 bellwether trials and plaintiffs' bar reports. Individual recovery depends on case-specific facts. AbbVie's global settlement terms are confidential. People's Justice does not guarantee any specific outcome.
Who Is at Risk: Testosterone Therapy Exposure Profiles
Common Tasks
- Uses testosterone therapy products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Common Tasks
- Uses testosterone therapy products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Common Tasks
- Uses testosterone therapy products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Common Tasks
- Uses testosterone therapy products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Internal Documents & Evidence
FDA Drug Safety Communication (January 2014) — Evaluating Risk of Stroke, Heart Attack, and Death
“”
Impact:
FDA 2015 Mandatory Label Change — Black Box VTE Warning and Indication Restrictions
“”
Impact:
MDL 2545 Bellwether Trial Results — Northern District of Illinois, 2017–2019
“”
Impact:
TOM Trial (NEJM 2010) — Landmark Study Stopped Early for Elevated Cardiovascular Events
“”
Impact:
Vigen et al. JAMA 2013 — Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke
“”
Impact:
Injured? Get a free Testosterone Therapy case review.
Get Your Free Case Reviewor call 1-800-555-0100
FDA Regulatory Actions Against Testosterone Replacement Therapy Products
FDA issued a Drug Safety Communication announcing it was evaluating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. The communication noted that two published studies raised concerns about cardiovascular risk. FDA directed manufacturers to update labeling and announced a formal safety review. This communication established that cardiovascular risk was recognized at the federal regulatory level — a key liability marker for lawsuits alleging failure to warn.
FDA convened its Endocrinologic and Metabolic Drugs Advisory Committee to evaluate cardiovascular safety evidence for testosterone products. The committee reviewed the TOM Trial data, the Vigen et al. JAMA 2013 study, and other post-market safety information. The committee voted that TRT labeling failed to adequately communicate cardiovascular risk and that approved indications should be narrowed. This advisory committee meeting preceded and directly informed the 2015 label change mandate — establishing regulatory knowledge and the inadequacy of existing warnings.
FDA mandated that all testosterone product labels include a warning about venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). This class-wide labeling change applied to every FDA-approved testosterone product. The mandate constituted an official regulatory finding that VTE risk was real, significant, and insufficiently disclosed by prior labeling — directly supporting failure-to-warn claims for patients who suffered DVT or PE before this date.
FDA required manufacturers to revise labels to restrict approved use to hypogonadism caused by underlying medical conditions (not age-related decline) and to add a statement that the cardiovascular risk of testosterone therapy had not been established. This restriction directly repudiated the 'Low T' marketing campaigns that drove mass prescribing, confirming that millions of men were prescribed testosterone outside of medically valid indications. The failure to restrict indications earlier — despite the 2010 TOM Trial evidence — supports claims that FDA-mandated warnings were unreasonably delayed.
The Testosterone in Older Men with Mobility Limitations (TOM) Trial, funded by the National Institutes of Health (NIH) and published in the New England Journal of Medicine, was stopped early by its Data Safety Monitoring Board after men in the testosterone group experienced significantly higher rates of cardiovascular adverse events compared to placebo. Events included heart attack, stroke, arrhythmia, and death. This landmark finding — published February 2010 — put manufacturers on notice of serious cardiovascular risk more than four years before the FDA's first Drug Safety Communication, a critical timeline fact for knowledge-based claims.
Significance Legend
Notable Verdicts & Settlements
The first bellwether trial in MDL 2545 resulted in a plaintiff verdict for a man who developed deep vein thrombosis while using AndroGel. The jury awarded approximately $150,000 in compensatory damages. This initial verdict established that juries could find AbbVie liable for TRT-related blood clot injuries and encouraged plaintiffs' attorneys to continue pursuing the MDL.
The second MDL 2545 bellwether trial — involving a plaintiff who suffered a myocardial infarction while using AndroGel — resulted in a defense verdict for AbbVie. The defense successfully argued that the plaintiff's pre-existing cardiovascular conditions were the primary cause of the heart attack, not TRT use. This verdict highlighted the causation challenge in MI cases with significant comorbidities.
A jury awarded over $140 million in punitive damages in a 2018 MDL 2545 bellwether trial against AbbVie. The award was the largest verdict in the litigation and reflected jury findings that AbbVie engaged in egregious marketing misconduct. The award was subsequently reversed on appeal and substantially remitted, but the verdict demonstrated the potential for significant punitive exposure and drove AbbVie's global settlement negotiations.
A fourth bellwether trial in MDL 2545 again resulted in a defense verdict for AbbVie. Defense arguments focused on plaintiff's significant pre-existing cardiovascular risk factors and lack of direct causation evidence linking AndroGel specifically to the cardiac event. The mixed bellwether record (2 plaintiff wins, 2 defense wins) complicated global settlement valuation.
AbbVie reportedly reached a confidential global settlement resolving the substantial majority of its MDL 2545 case inventory — estimated by plaintiffs' attorneys at $250M–$500M total. The exact terms remain undisclosed. The settlement covered non-bellwether AndroGel cases consolidated in MDL 2545. Individual plaintiff amounts varied by injury severity. Cases involving Eli Lilly (Axiron), Actavis/Teva (Androderm), and Endo successor entities were not included.
Injured? Get a free Testosterone Therapy case review.
Get Your Free Case Reviewor call 1-800-555-0100
Heart Attack (Myocardial Infarction)
Medical Definition
A myocardial infarction (MI) occurs when blood flow to a section of heart muscle is blocked, causing tissue death. Testosterone therapy increases red blood cell count (polycythemia) and may promote arterial plaque buildup (atherosclerosis), raising the risk of coronary artery occlusion. Multiple large studies, including a 2013 JAMA analysis of over 55,000 men, found a 30% increased MI risk in TRT users.
Symptoms
Chest pain or pressure (angina)
CommonShortness of breath
CommonPain radiating to left arm, jaw, or back
CommonSudden sweating and nausea
CommonRapid or irregular heartbeat
CommonRisk Factors
- Testosterone therapy use (gel, patch, injection)
- Pre-existing hypertension or hyperlipidemia
- Age over 45
- Obesity or metabolic syndrome
- Smoking history
- Polycythemia induced by TRT (hematocrit >54%)
Treatment Options
Stroke (Ischemic and Hemorrhagic)
Medical Definition
Stroke occurs when blood supply to part of the brain is interrupted (ischemic) or a blood vessel ruptures (hemorrhagic). Testosterone therapy's thrombogenic effects — including increased platelet aggregation and elevated hematocrit — raise stroke risk. A 2014 PLOS ONE study found a 100% increased stroke risk in younger TRT users with pre-existing heart disease.
Symptoms
Sudden facial drooping on one side
CommonArm weakness or numbness (one side)
CommonSlurred or confused speech
CommonSudden severe headache without cause
CommonVision disturbance in one or both eyes
CommonLoss of balance or coordination
CommonRisk Factors
- Current testosterone therapy use
- Atrial fibrillation
- Hypertension
- Prior TIA (transient ischemic attack)
- Polycythemia from TRT use
- Age over 50
Treatment Options
Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Medical Definition
Deep vein thrombosis is the formation of a blood clot in a deep vein, typically in the leg. If the clot breaks free and travels to the lungs, it becomes a pulmonary embolism — a life-threatening emergency. Testosterone stimulates erythropoiesis (red blood cell production), raising hematocrit and blood viscosity, dramatically increasing clotting risk. The FDA issued its 2015 black box warning specifically for this VTE risk.
Symptoms
Leg swelling, pain, or warmth (DVT)
CommonRed or discolored skin on affected leg
CommonSudden shortness of breath (PE)
CommonChest pain worsening with deep breath (PE)
CommonRapid heartbeat or dizziness (PE)
CommonCoughing up blood (PE, severe)
SevereRisk Factors
- Testosterone therapy use — primary mechanism via polycythemia
- Immobility or recent surgery
- Factor V Leiden or other clotting disorders
- Obesity
- Prior DVT or PE history
- Long-distance travel during TRT use
Treatment Options
Polycythemia (Elevated Red Blood Cell Count)
Medical Definition
Polycythemia is an abnormal increase in red blood cells, raising blood viscosity and clotting risk. Testosterone directly stimulates erythropoiesis (red blood cell production) in bone marrow. Hematocrit levels above 54% are considered dangerous. TRT-induced polycythemia is a known adverse effect — it is listed in product labeling — but many prescribers failed to monitor hematocrit levels during therapy, allowing the condition to progress undetected and increasing cardiovascular event risk.
Symptoms
Headaches and dizziness
CommonBlurred vision
CommonRedness or flushing of face and hands
CommonItching, especially after hot shower
CommonShortness of breath
CommonFatigue and weakness
CommonRisk Factors
- Testosterone therapy — direct mechanism
- Injectable testosterone (highest risk form)
- Failure of physician to monitor hematocrit during TRT
- Dehydration
- Sleep apnea (exacerbates TRT-induced polycythemia)
Treatment Options
Your Legal Team
People's Justice — Illinois TRT Legal Team
Our Chicago-based attorneys represent plaintiffs in MDL 2545 — In re: Testosterone Replacement Therapy Products Liability Litigation — pending in the Northern District of Illinois. With the MDL home court located in Chicago, we have direct familiarity with case management orders, bellwether trial outcomes, and the current settlement landscape for remaining defendants including Eli Lilly and Actavis/Teva. We handle AndroGel, Axiron, Androderm, and Endo bankruptcy trust claims.
People's Justice — Texas TRT Legal Team
Our Texas attorneys serve TRT plaintiffs across Houston, Dallas, San Antonio, and statewide. Texas has a 2-year statute of limitations for personal injury claims running generally from the injury date — time is critical. Houston is among the highest-volume markets for testosterone therapy cardiovascular injury claims nationally, driven by high male 45–75 population density and historically elevated TRT prescription rates in the region.
People's Justice — Florida TRT Legal Team
Our Florida attorneys represent TRT injury plaintiffs statewide including Miami, Jacksonville, Orlando, and Tampa. Florida's statute of limitations for personal injury was reduced from 4 years to 2 years effective March 24, 2023 under SB 236. Plaintiffs who have not yet filed face an urgent deadline. Florida's large retiree population and historically high TRT marketing saturation make it one of the top plaintiff-density states in MDL 2545.
Frequently Asked Questions
Testosterone Therapy Lawsuit Filing Deadlines
In-Depth Guides
AbbVie's AndroGel was the #1 selling testosterone gel in the U.S. with over $1 billion in annual sales at peak. AbbVie is accused of marketing AndroGel to men with normal age-related hormone decline without adequate cardiovascular warnings. MDL 2545 in Chicago has processed over 10,000 AndroGel cases. AbbVie reportedly settled its MDL inventory for an estimated $250M–$500M (confidential). New cases are still being filed.
Read guideAxiron (Eli Lilly) is an underarm testosterone gel marketed from 2011. Androderm (Actavis/Allergan, now Teva) is a transdermal patch. Both products are named in MDL 2545, and both defendants — unlike AbbVie — have not yet completed global settlement of their MDL inventory. Men who used Axiron or Androderm and suffered cardiovascular injuries may be in a strong position as these defendants move toward resolution.
Read guideTestosterone therapy directly stimulates red blood cell production (erythropoiesis), raising hematocrit and blood viscosity — a known mechanism for DVT and pulmonary embolism. The FDA's 2015 black box warning specifically called out venous thromboembolism (VTE) risk. DVT/PE cases that resolved without permanent injury typically settle in the $15,000–$75,000 range; PE cases requiring hospitalization or with lasting effects may settle higher.
Read guideThe primary defendants in MDL 2545 are AbbVie (AndroGel), Eli Lilly (Axiron), Actavis/Allergan/Teva (Androderm), Pfizer (Depo-Testosterone), and Endo Pharmaceuticals (Testim, Fortesta — now in Chapter 11 bankruptcy). AbbVie's MDL docket is largely resolved via confidential settlement. Eli Lilly and Actavis/Teva remain in active litigation. Endo plaintiffs must file through bankruptcy trust.
Read guideThe four essential evidence categories are: (1) TRT prescription or pharmacy records showing product, duration, and dose; (2) medical records documenting your cardiovascular injury (hospital records, discharge summaries, cardiac catheterization or imaging results); (3) a timeline showing TRT use preceded the cardiac event; and (4) any hematocrit or CBC lab results from during TRT use. An attorney can help obtain records via medical release authorization at no cost to you.
Read guideIn March 2015, the FDA required the strongest safety label — a black box warning — on all testosterone products for venous thromboembolism (VTE) risk, including DVT and PE. The FDA simultaneously restricted approved TRT uses to men with medical-condition hypogonadism only, excluding normal aging. The 2014 FDA Drug Safety Communication may trigger the discovery rule clock in some states. The 2015 black box warning is the most legally significant regulatory event in TRT litigation.
Read guideStatutes of limitations for TRT lawsuits vary by state — typically 2–3 years from injury discovery. Florida reduced its SOL to 2 years effective March 2023. The 2014 FDA Drug Safety Communication may trigger the discovery rule clock in some states. Filing a Short Form Complaint in MDL 2545 provides tolling protection. Endo bankruptcy trust claims have court-set deadlines. If your cardiac event was more than 18 months ago, contact an attorney immediately.
Read guideThe 2010 TOM Trial was stopped early due to excess cardiovascular events. A 2013 JAMA study found a 29% increased MI risk in TRT users. A 2014 PLOS ONE study found doubled MI risk in men under 65 with pre-existing heart disease within 90 days of starting TRT. The FDA acted in 2014 and 2015. Men who suffered heart attacks while on TRT may have a strong legal claim.
Read guide"Low T" — hypogonadism framed as a widespread treatable epidemic — was substantially created by pharmaceutical industry disease-awareness campaigns beginning around 2008. AbbVie spent hundreds of millions on direct-to-consumer AndroGel advertising. Eli Lilly and Actavis ran similar campaigns for Axiron and Androderm. The campaigns targeted men experiencing normal aging symptoms — fatigue, reduced libido, mild mood changes — that had never previously been treated as a medical condition requiring daily hormone therapy.
Read guideMDL 2545 — In re: Testosterone Replacement Therapy Products Liability Litigation — is pending in the Northern District of Illinois (Chicago). AbbVie's MDL inventory is largely resolved via confidential global settlement. Eli Lilly (Axiron) and Actavis/Teva (Androderm) cases remain in active negotiation. Endo (Testim/Fortesta) claims require Endo bankruptcy trust filing. New individual cases continue to be filed in both federal and state courts.
Read guideThe four primary qualifying injuries are: heart attack (myocardial infarction), stroke (ischemic or hemorrhagic), deep vein thrombosis (DVT), and pulmonary embolism (PE). Polycythemia that caused or contributed to a cardiovascular event may also qualify. Injury must have occurred during or within 6 months of TRT use, and you must have used a qualifying TRT product for at least 30 days.
Read guideAbbVie reportedly settled its MDL 2545 inventory for an estimated $250M–$500M (confidential terms). Individual per-plaintiff values: DVT/PE without permanent injury ($15K–$75K), heart attack with recovery ($75K–$250K+), stroke or disability ($200K–$600K), wrongful death ($250K–$1M+). Bellwether verdicts ranged from $150K to $140M (later reduced on appeal). Remaining defendants Eli Lilly and Actavis/Teva continue negotiations.
Read guide